Synthetic Approaches towards the Sulfonamide Substituted-1,5-Diarylimidazole-2-thiones as Selective Cyclooxygense-2 inhibitors-Reference-Cited by-同舟云学术

Synthetic Approaches towards the Sulfonamide Substituted-1,5-Diarylimidazole-2-thiones as Selective Cyclooxygense-2 inhibitors

Published:2013-10-08 Issue:1 Volume:51 Page:71-79
ISSN:0022-152X
Container-title:Journal of Heterocyclic Chemistry
language:en
Short-container-title:J. Heterocyclic Chem.

Author:

Navidpour Latifeh¹,Amini Mohsen¹,Miri Ramin²,Firuzi Omidreza²,Tavakkoli Marjan²,Shafiee Abbas¹

Affiliation:

1. Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center; Tehran University of Medical Sciences; Tehran 14176 Iran

2. Medicinal and Natural Products Chemistry Research Center; Shiraz University of Medical Sciences; P.O. Box 3288-71345 Shiraz Iran

Publisher

Wiley

Subject

Organic Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jhet.1695/fullpdf

Reference35 articles.

1. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

2. A Practical Synthesis of a COX-2-Specific Inhibitor

3. Cyclooxygenase-2: A Therapeutic Target

4. Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years;Acta Pharmaceutica Sinica B;2022-06

2. Selective cyclooxygenase-2 inhibitors: A review of recent chemical scaffolds with promising anti-inflammatory and COX-2 inhibitory activities;Medicinal Chemistry Research;2020-03-09

3. Synthesis and Biological Profiles of 4,5-, 1,5-, and 1,2-Diaryl-1 H -imidazoles;Vicinal Diaryl Substituted Heterocycles;2018

4. Hydroxycinnamic acid as a novel scaffold for the development of cyclooxygenase-2 inhibitors;RSC Advances;2015